CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 408 enrolled
Drug / intervention
Maxigesic 325 +3 moredrug
Likely dose
Maxigesic 325 325 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01420653
NCT01420653Phase 3Completed

Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain

AFT Pharmaceuticals, Ltd.·interventional·Posted Aug 22, 2011·Updated Dec 6, 2018

In Brief

A Phase 3 clinical trial evaluating Maxigesic 325, Acetaminophen, and 2 other interventions for Dental Pain. Completed, enrolled 408 participants across 4 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDental Pain
CountriesNew Zealand, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 22, 2011
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.9 years ago

Interventions

Maxigesic 325drug

Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours

Acetaminophendrug

Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours

Ibuprofendrug

Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.

Placebodrug

placebo, three tablets four times a day, with food for 48 hours